Answer
Rifampicin and enzalutamide, moderate or strong dual CYP3A4/5 and CYP2C9 inducers, reduce avatrombopag exposure when used concomitantly with Doptelet (avatrombopag maleate), potentially decreasing its effect on platelet counts.
Sources for this answer
- Doptelet 20 mg film coated tabletsSwedish Orphan Biovitrum Ltd · emc · SmPC §4.5 Interaction with other medicinal products · Version 6Document updated
Sources checked